Faron Pharmaceuticals

0.54 EUR

+2.47 %

5,722 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

+2.47 %
+20.94 %
-10.09 %
-72.94 %
-73.70 %
-80.69 %
-82.68 %
-87.03 %
-83.83 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
109.64M EUR
Turnover
599.59K EUR
P/E (adj.) (26e)
-5.23
EV/EBIT (adj.) (26e)
-6.06
P/B (26e)
93.71
EV/S (26e)
28,771.2
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
That “made up out of thin air” remark is quite unnecessary and doesn’t exactly encourage one to keep writing here. The fact that an interpretation needs clarification doesn’t mean the matter was fabricated. The 9.99% condition is found in the terms of Faron’s debt restructuring arrangement...
11 hours ago
by Pati_
24
The diseases are different. If MDS is rare, that one is ultra-rare. It is more difficult to build a comparative setting. BEXMAB was a combination with Aza, so the FDA wants to see what portion of the efficacy is attributed to Bex in a comparative setting. That was a monotherapy, ...
yesterday
by Vino Pino
21
Couldn’t this Bank of America situation be considered quite a positive thing in the short term, if I’m interpreting this correctly? That position consists entirely of financial instruments. This means HCM or other guarantors have already managed to share or hedge part of the risk...
14 hours ago
by Makkispekkis1
9
I would interpret this slightly differently. In my view, the more likely explanation is that they are managing HCM’s 9.99 percent ownership limit. In a previous flagging notification, HCM already had a direct shareholding of approximately 9.55 percent, meaning it was practically ...
13 hours ago
by Pati_
7
If nearly 10% of the share capital is flagged to someone, then SOMEONE’S holding is definitely decreasing radically.
yesterday
by Kulkuri
6
Who could explain why the FDA approved that drug based on such a small patient population (33 + 51 r/r) and how that compares to BEX? FDA Approves Pivekimab Sunirine for Rare Blood Cancer https://www.oncologynewscentral.com/drugs/info/fda-approves-pivekimab-sunirine-for-rare-blood...
yesterday
by Kulkuri
5
Or then they have been looking for a party that wants to buy a larger block of shares at once, and BoA might want to play the long game either for themselves or on behalf of a third party. All scenarios are possible; it would be nice to get a comment from the parties involved, should...
12 hours ago
by MyrtsiZzz
4
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.